Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01621386 · ClinicalTrials.gov registry record · Phase 1

Ventilatory Heterogeneity in Participants With Asthma (MK-0476-513)

A Phase 1 study, sponsored by Hal C Charles.

Completed
Registry status
Phase 1
Development phase
34
Enrollment target

NCT01621386 is a Phase 1 study that has completed, run by Hal C Charles. The registered enrollment target is 34 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01621386, a Phase 1 study, has completed, sponsored by Hal C Charles.

COMPLETED
Registry status
Phase 1
Development phase
34 participants
Enrollment target

Study Summary

This study will explore the utility of magnetic resonance imaging (MRI) to assess ventilatory defects that occur due to asthma, determine the sensitivity and specificity of MRI in response to drug treatment, and whether MRI can serve as a biomarker of treatment effects due to asthma therapy.

Interventions

  • DRUG Prednisone
  • DRUG Montelukast

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2013-01
Est. Completion 2016-03
Phase Phase 1

Sponsor

Hal C Charles

7 total trials

What the Registry Record Tells You About NCT01621386

The ClinicalTrials.gov registry entry for NCT01621386 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hal C Charles, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Prednisone is the first listed.

NCT01621386 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01621386 about?

NCT01621386 is a clinical study titled "Ventilatory Heterogeneity in Participants With Asthma (MK-0476-513)". This study will explore the utility of magnetic resonance imaging (MRI) to assess ventilatory defects that occur due to asthma, determine the sensitivity and specificity of MRI in response to drug treatment, and whether MRI can serve as a biomarker of treatment effects due to asthma therapy.

What is the current status of trial NCT01621386?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2013-01. Estimated completion is 2016-03.

What interventions are being tested in trial NCT01621386?

The interventions under investigation include: Prednisone (DRUG), Montelukast (DRUG).

Who is sponsoring clinical trial NCT01621386?

This trial is sponsored by Hal C Charles, which has 7 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.